GALECTO INC
NASDAQ: GLTO (Galecto, Inc.)
Kemas kini terakhir: 10 jam lalu28.91
0.55 (1.94%)
| Penutupan Terdahulu | 28.36 |
| Buka | 28.31 |
| Jumlah Dagangan | 117,610 |
| Purata Dagangan (3B) | 177,676 |
| Modal Pasaran | 1,741,540,480 |
| Harga / Buku (P/B) | 268.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 |
| EPS Cair (TTM) | -15.40 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.53% |
| Nisbah Semasa (MRQ) | 9.62 |
| Aliran Tunai Operasi (OCF TTM) | -15.13 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.59 M |
| Pulangan Atas Aset (ROA TTM) | -35.94% |
| Pulangan Atas Ekuiti (ROE TTM) | -88.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Galecto, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -1.50 |
|
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.69% |
| % Dimiliki oleh Institusi | 13.02% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |